Double-blind, randomized, placebo-controlled, cross-over study of intranasal oxytocin augmentation of antipsychotic medication in schizophrenia patients.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Oxytocin (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 25 Sep 2019 Biomarkers information updated
- 08 Aug 2011 Planned end date changed from 1 Mar 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 19 Jan 2011 Primary endpoint 'Positive-and-Negative-Syndrome-Scale' has been met